Why and how have drug discovery strategies in pharma changed? What are the new mindsets?

被引：55

作者：

Mignani, Serge ^{[1
]}

Huber, Scot ^{[2
]}

Tomas, Helena

Rodrigues, Joao ^{[3
]}

Majoral, Jean-Pierre ^{[4
,5
]}

机构：

[1] Univ Paris 05, CNRS UMR 860, Lab Chim & Biochim Pharmacol & Toxicol, PRES Sorbonne Paris Cite, 45 Rue St Peres, F-75006 Paris, France

[2] SCYNEXIS Inc, POB 12878, Res Triangle Pk, NC 27709 USA

[3] Univ Madeira, CQM, MMRG, Campus Univ Penteada, P-9000390 Funchal, Portugal

[4] CNRS, Lab Chim Coordinat, 205 Route Narbonne,BP 44099, F-31077 Toulouse 4, France

[5] Univ Toulouse, UPS, INPT, F-31077 Toulouse 4, France

来源：

DRUG DISCOVERY TODAY | 2016年 / 21卷 / 02期

关键词：

CHEMICAL BEAUTY; OPEN INNOVATION; 1ST-IN-CLASS; CHALLENGES; REVOLUTION; IMPACT; SPACE;

D O I：

10.1016/j.drudis.2015.09.007

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

In the pharmaceutical industry the long-term challenge of drug innovation is the key phrase throughout R&D that refers to increasing the output of original drug candidate molecules. To increase R&D productivity, implementation of new and strategic R&D orientations to develop new approaches or systems to identify hits and leads efficiently has taken place and enabled all scientists working in the drug discovery domain to develop innovative medicines for the 21st century.

引用

页码：239 / 249

页数：11

共 88 条

[1] Ligand efficiency indices for an effective mapping of chemico-biological space: the concept of an atlas-like representation [J].

Abad-Zapatero, Cele ;

Perisic, Ognjen ;

Wass, John ;

Bento, A. Patricia ;

Overington, John ;

Al-Lazikani, Bissan ;

Johnson, Michael E. .

DRUG DISCOVERY TODAY, 2010, 15 (19-20) :804-811

[2] Discovery of Innovative Small Molecule Therapeutics [J].

Abou-Gharbia, Magid .

JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (01) :2-9

[3] Returns on R&D investments continue to fall [J].

不详 .

NATURE REVIEWS DRUG DISCOVERY, 2014, 13 (01) :9-9

[4]

[Anonymous], APPL CLIN TRIALS, P16

[5]

[Anonymous], APPL CLIN TRIALS, P8

[6]

[Anonymous], 2013, NAT REV DRUG DISCOV, V12, P568

[7]

[Anonymous], 2012, PHARM TECHNOL EUR, P8

[8]

Arlington S., 2012, DRUG DISCOV WORLD

[9] Defining rewardable innovation in drug therapy [J].

Aronson, Jeffrey K. ;

Ferner, Robin E. ;

Hughes, Dyfrig A. .

NATURE REVIEWS DRUG DISCOVERY, 2012, 11 (04) :253-254

[10] Phase II failures: 2008-2010 [J].

Arrowsmith, John .

NATURE REVIEWS DRUG DISCOVERY, 2011, 10 (05) :1-1

← 1 2 3 4 5 6 7 8 9 →